Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | CA2 | P00918 | 4/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 2/20 | 0.48 |
| ▸ | CES1 | P23141 | 2/20 | 0.48 |
| ▸ | PLK1 | P53350 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4806906 | 1.00 | ALDH1A1 (0.52) | ALDH1A1GAACA1CA2PKM | |
| SCHEMBL28120573 | 0.85 | PPARG (0.61) | ALDH1A1GAACA1CA2PKM | |
| SCHEMBL15239274 | 0.85 | CA1 (0.48) | ALDH1A1GAACA1CA2MEN1 | |
| SCHEMBL15239276 | 0.85 | CA1 (0.48) | ALDH1A1GAACA1CA2MEN1 | |
| SCHEMBL8017837 | 0.84 | TSHR (0.48) | ALDH1A1GAAMEN1KMT2ACES1 | |
| SCHEMBL8017835 | 0.84 | TSHR (0.48) | ALDH1A1GAAMEN1KMT2ACES1 | |
| SCHEMBL4807901 | 0.83 | PPARG (0.44) | ALDH1A1GAAMEN1KMT2AKDM4E | |
| SCHEMBL4807912 | 0.83 | PPARG (0.44) | ALDH1A1GAAMEN1KMT2AKDM4E | |
| SCHEMBL4809724 | 0.81 | ALDH1A1 (0.51) | ALDH1A1GAACA1CA2PKM | |
| SCHEMBL4809728 | 0.81 | ALDH1A1 (0.51) | ALDH1A1GAACA1CA2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390925-B2 | Oxime-containing acyl guanidines as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-24 | — | — | US | disclosed |
| US-7390925-B2 | Oxime-containing acyl guanidines as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-24 | — | — | US | disclosed |
| US-20070232581-A1 | Oxime-Containing Acyl Guanidines as Beta-Secretase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-04 | — | — | US | disclosed |
| US-20070232581-A1 | Oxime-Containing Acyl Guanidines as Beta-Secretase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232581-A1 | Oxime-Containing Acyl Guanidines as Beta-Secretase Inhibitors | BACE1, APP, BACE2 | ALDH1A1 1599/4885GAA 70/4885CA1 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.